Press Room

News / Aug 09, 2021

Our knowledge is available 365 days for you

Summer series

Knowledge 365 our experts content always available | Hovione

Our knowledge is available 365 days for you.

Count on our multidisciplinary teams to exchange knowledge, ideas, and experience to develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.

Challenge us

 

Our scientists attend the leading events of the pharma industry throughout the year where they share their knowledge and present their innovative work.

 

Did you miss the articles on Pharmaceutical Technology, Drug Development & Delivery, On-Drug Delivery or Chemistry Today? You are still in time to read them. Access them here: 

 

pharmatech logo | Hovione

 

Drug Development and Delivery Logo | Hovione

 



Moving Beyond

Particle Size Control




Contributors:

João Henriques (Group Leader,

R&D Drug Product Development)

Mafalda Paiva (Group Leader, Analytical Development)


 


Improving Bioavailability

& Solubility: Each Molecule

Is Unique - Emerging Platforms

Address Extreme Compounds




Contributor: João Henriques

(Group Leader, R&D

Drug Product Development)


 
ondrugdelivery logo | Hovione

 

chemistry today chimica oggi logo | Hovione

 



Semi-Automation in

Inhaler Testing - Exploring

the Potential & Practicalities




Discussion with João Pereira

(Team Leader, R&D Analytical Development)

Raquel Borda d' Água

(Associate Analytical Chemist, R&D Analytical Development; Copley) 


 


Where Continuous Flow

can help in today’s

Pharmaceutical Industry




Panel Discussion with

Rudi Oliveira

(Scientist, R&D Process

Engineering and Scale-up)









































 

 

 

 

 

 

 

Did you miss our presentations at DDF, RDD, DDL or AIChE?

You are still in time to join. Access them here:

 

 

ddf summit 2021 logo | Hovione

 

rdd 2021 logo | Hovione

 



Technology & Innovation



Performance Enhancement Strategies for

Low Solubility APIs – do more with less




Authors: Mafalda Paiva &

João Henriques

 



Workshop Presentation



Fully Integrated

DPI Development

From API To Device




Authors: João Pereira,

Beatriz Noriega Fernandes

aiche 2020 logo | Hovione

 

ddl 2020 logo | Hovione

 



Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals



Reaction Kinetic Model

Application to Speed up Development




Author: Filipe Ataíde

 



Presentation

and Paper



Spray-dried composite

formulation for lung

sustained release




Author: Beatriz Noriega Fernandes

















































































 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026